Imatinib Stada

Imatinib, the active ingredient in Imatinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet (strength not specified) for systemic use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients, targeting malignant cell proliferation.

GNH USA supplies Imatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU GMP guidelines and offers a reliable supply chain for oncology therapeutics across multiple continents.

Imatinib acts on malignant cells driven by BCR‑ABL and related tyrosine kinases, making it a cornerstone therapy for certain hematologic and solid tumours. - Chronic myeloid leukemia (CML): reduces leukemic cell burden and improves long‑term survival. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and delays disease progression. - Philadelphia chromosome‑positive acute lymphoblastic leukaemia (Ph+ ALL): contributes to remission when combined with chemotherapy.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of the hands, feet, or face. - Fatigue: persistent tiredness. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Neutropenia: significant drop in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced heart function. - Severe haemorrhage: unusual bleeding. - Pulmonary hypertension: increased pressure in lung arteries.

Patients and prescribers should observe several safety measures. - Monitor blood counts: regular CBC to detect cytopenias. - Assess liver function: periodic LFTs for hepatotoxicity. - Evaluate cardiac status: baseline and follow‑up cardiac assessments. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Counsel on drug interactions: review concomitant medications. - Store at room temperature: keep in the original pack, protect from moisture.

Imatinib may interact with several co‑administered agents.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase imatinib exposure. - Potent CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels. - Antacids containing aluminium or magnesium: can impair absorption.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam): may require dose adjustment. - Diuretics (e.g., furosemide): monitor electrolytes and renal function.